Plus Therapeutics Inc (CNSY) Stock Analysis
Verdict: AVOID
Severe cash burn ($20.8M FCF loss in 2025) forces constant toxic dilution and debt deals, overriding early-stage clinical potential.
Investment score: 23/100
Analysis as of
Is Plus Therapeutics Inc stock worth reviewing? The TradeMates thesis
The model rates CNSY as an AVOID due to severe cash burn, relentless share dilution, debt overhang, and four consecutive earnings misses.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Plus Therapeutics Inc opportunities and risks
What speaks for CNSY
- Expanding CNSide diagnostic coverage with national payers
What speaks against CNSY
- Relentless common stock dilution from ATM facilities and warrant overhang
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CNSY | n/a | 3.0x | n/a | 89.6% | -620.7% | -188.0% |
| KTTA | n/a | 0.0x | 1.4x | 0.0% | 0.0% | -129.1% |
| BCDA | n/a | 0.0x | n/a | 0.0% | 0.0% | -55.7% |
| SYBX | n/a | 0.0x | 0.0x | 0.0% | 0.0% | -29.3% |
| VICP | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.2% |
| AEON | n/a | 0.0x | n/a | 0.0% | 0.0% | -118.4% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -55.7% |
Frequently asked questions about Plus Therapeutics Inc (CNSY)
Is CNSY stock a good investment?
The TradeMates model rates Plus Therapeutics Inc as AVOID with an investment score of 23/100. The model rates CNSY as an AVOID due to severe cash burn, relentless share dilution, debt overhang, and four consecutive earnings misses. This is algorithmic model output, not personal investment advice.
Is CNSY stock a buy?
The TradeMates model verdict for CNSY is AVOID with an investment score of 23/100. Treat this as a model signal to review, not a personal buy recommendation.